Supplements
coffee decreases liver disease risk
In plain terms: Is coffee good for your liver?
Part of: • Coffee
This is one of coffee's strongest health links. Coffee drinkers have substantially lower rates of liver cancer, cirrhosis, and scarring (fibrosis) - often 40-50% lower at higher intakes. It seems to protect against liver-disease *progression* more than preventing fatty liver in the first place, but the signal is remarkably consistent.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
Coffee has an unusually strong and consistent link to **better liver health**: meta-analyses report substantially lower risk of liver cancer (HCC), cirrhosis, and advanced fibrosis in coffee drinkers, often 40–50% lower at higher intake, with a clear dose-response. The main caveat is that the benefit is clearest for **liver-disease progression and cancer**, not for simply developing fatty liver in
The evidence (14)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Kennedy OJ et al. 2017 · BMJ Open | meta-analysis | supports | high | SR+meta 18 cohorts (2.27M): +2 cups/d gives 35% lower HCC (RR 0.65); GRADE very low (no RCTs). |
| Kositamongkol C et al. 2021 · Front Pharmacol | meta-analysis | mixed | moderate | Umbrella: no assoc with NAFLD incidence generally; reduced fibrosis in NAFLD patients (OR 0.67). |
| Goh GB et al. 2014 · Hepatology | observational | supports | high | Singapore Chinese (63k): >=2 cups/d nonviral cirrhosis mortality HR 0.34. |
| Liu F et al. 2015 · PLoS One | meta-analysis | supports | moderate | Meta 16 studies: cirrhosis OR 0.61, fibrosis OR 0.73, dose-dependent. |
| Park SY et al. 2018 · Cancer Epidemiol Biomarkers Prev | observational | supports | high | Multiethnic Cohort (167k): >=4 cups/d liver cancer HR 0.57, consistent across 5 ethnicities. |
| Di Maso M et al. 2021 · Adv Nutr | meta-analysis | mixed | moderate | Dose-response meta: HCC RR 0.93 (0.80-1.08), trending protective but not statistically significant. |
| Ebadi M et al. 2021 · Nutrients | meta-analysis | mixed | moderate | Meta: no assoc with NAFLD incidence (RR 0.88 ns) BUT 35% lower significant fibrosis (RR 0.65). |
| Yu C et al. 2016 · Sci Rep | meta-analysis | supports | high | Dose-response meta 20 cohorts: highest vs occasional liver cancer RR 0.55; linear dose-response. |
| Bravi F et al. 2017 · Eur J Cancer Prev | meta-analysis | supports | high | Meta: HCC RR 0.66 and chronic liver disease RR 0.62 in coffee drinkers. |
| Setiawan VW et al. 2015 · Gastroenterology | observational | supports | high | Multiethnic Cohort (162k): >=4 cups/d HCC RR 0.59; chronic-liver-disease mortality RR 0.29. |
| Whitfield JB et al. 2021 · J Hepatol | observational | tested-null | moderate | Coffee did NOT improve genetic/clinical risk-score prediction of alcohol-related cirrhosis (null). |
| Bravi F et al. 2013 · Clin Gastroenterol Hepatol | meta-analysis | supports | high | Meta 16 studies: any coffee HCC RR 0.60; high intake RR 0.44. |
| Bai K et al. 2016 · Onco Targets Ther | meta-analysis | supports | moderate | Meta 11 studies: HCC pooled OR 0.49. |
| Hayat U et al. 2020 · Ann Hepatol | meta-analysis | supports | moderate | Meta 11 studies: NAFLD RR 0.77; lower fibrosis risk. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.